A Phase 4 interventional study of Zolpidem 10 mg tablets and Avocado-soybean unsaponifiables 300 mg in Postoperative Pain Management in Total Knee Arthroplasty, sponsored by Sanatorio Allende. Completed at 1 site in Argentina. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-03.
Sponsored by Sanatorio Allende · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies testing zolpidem in Sleep Initiation and Maintenance Disorders — 2 open to participants now, 2 under way, 1 of them phase 3. Zolpidem · Sleep Initiation and Maintenance Disorders.
Among the 40 studies testing zolpidem in Sleep Initiation and Maintenance Disorders, this one is the 28th largest by enrollment, is the only one that started in 2025, is one of 19 in phase 4, and was the 40th registered.
2,732 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 733 are open to participants now.
Browse Sleep Initiation and Maintenance Disorders studies →2 of the 40 studies testing zolpidem in Sleep Initiation and Maintenance Disorders are open now, in 1 country. Recruiting first, the newest first:
Emory University · Sites in United States
Ages 18–65
University of Pennsylvania · Sites in United States
Ages 18–80
By country, each count listing its studies:
Zolpidem: first FDA approval 1992 (AMBIEN). What it is approved for, and how studies give it, is on its page →
Of the 392 Sleep Initiation and Maintenance Disorders studies recruiting now, 155 (40%) set no upper age limit and 207 (53%) stop at 75 or younger; 59 take children under 18; 110 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 8 · Phase 3 7 · Phase 4 19
First in 2001; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 54 is below the median of 68 across 2,359 interventional studies indexed under Sleep Initiation and Maintenance Disorders.
Median enrollment 108 across the 40 interventional studies. Of the 37 that completed or were terminated, 14 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 40 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Sanatorio Allende as lead sponsor.
Sanatorio Allende has 1 study filed under Sleep Initiation and Maintenance Disorders — fewer than ten, so there is no comparison to draw.
1 of the studies testing zolpidem in Sleep Initiation and Maintenance Disorders that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07336277Phase 3Emory UniversitySleep Quality and the Efficacy of a Multimodal Sleep Pathway in Hospitalized Orthopedic Trauma Patients | 2027-07 |
Add it to your calendar (.ics) → With an account.
Among the 40 studies testing zolpidem in Sleep Initiation and Maintenance Disorders, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This clinical trial evaluated whether zolpidem could improve sleep quality and postoperative recovery in patients undergoing total joint arthroplasty. Participants were randomly assigned to receive either zolpidem 10 mg or a placebo for 14 nights, beginning after hospital discharge. Neither the participants nor their physicians knew which treatment was assigned. The study assessed sleep quality and duration, postoperative pain, use of pain medications, functional recovery, satisfaction, and adverse events. The study hypothesis was that improving sleep with zolpidem would lead to better sleep and potentially improve pain control and recovery after surgery compared with placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants assigned to this arm received placebo orally once nightly for 14 consecutive nights after total knee arthroplasty.
Drug: Avocado-soybean unsaponifiables 300 mg
Participants assigned to this arm received zolpidem 10 mg orally once nightly for 14 consecutive nights after total knee arthroplasty.
Drug: Zolpidem 10 mg tablets
Zolpidem 10 mg was administered orally once nightly for 14 consecutive nights following total knee arthroplasty.
Avocado-soybean unsaponifiables (Prontal) 300 mg were administered orally once nightly for 14 consecutive nights following total knee arthroplasty.
Postoperative Pain Intensity Assessed Using the Numeric Rating Scale
Postoperative pain intensity was assessed using an 11-point Numeric Rating Scale (NRS), ranging from 0 (no pain) to 10 (worst imaginable pain). Higher scores indicated greater pain intensity.
Time frame: Postoperative days 7 and 14
Postoperative Sleep Quality Assessed Using a 5-Point Likert Scale
Overall postoperative sleep quality was assessed using a study-specific question rated on a 5-point Likert scale. The question was selected with reference to conceptual domains of the Pittsburgh Sleep Quality Index (PSQI); however, the PSQI itself was not administered or scored. Higher scores indicated better perceived sleep quality.
Time frame: Postoperative days 7 and 14
Pain-Related Interference With Sleep
Pain-related interference with sleep was assessed using a study-specific question evaluating whether postoperative pain interfered with the patient's sleep.
Time frame: Postoperative days 7 and 14
Postoperative Analgesic Consumption
Postoperative analgesic consumption was assessed using a study-specific questionnaire recording the patient's use of analgesic medication during the postoperative period.
Time frame: Postoperative days 7 and 14
Use of Rescue Tramadol
Use of rescue tramadol for postoperative pain management was recorded using a study-specific questionnaire.
Time frame: Postoperative days 7 and 14
Participation in Postoperative Rehabilitation
Participation in postoperative rehabilitation was assessed using a study-specific questionnaire recording whether the patient was participating in rehabilitation activities.
Time frame: Postoperative days 7 and 14
Daily Duration of Postoperative Rehabilitation
The duration of postoperative rehabilitation was assessed by patient report and recorded as the average number of minutes of rehabilitation performed per day.
Time frame: Postoperative days 7 and 14
Self-Reported Mobility Compared With Hospital Discharge
Postoperative mobility was assessed using a study-specific question in which patients reported their mobility relative to their mobility at the time of hospital discharge.
Time frame: Postoperative days 7 and 14
Patient Satisfaction With Sleep Quality Assessed Using a 5-Point Likert Scale
Patient satisfaction with postoperative sleep quality was assessed using a study-specific 5-point Likert scale. Higher scores indicated greater satisfaction with sleep quality.
Time frame: Postoperative days 7 and 14
Patient Satisfaction With Pain Management Assessed Using a 5-Point Likert Scale
Patient satisfaction with postoperative pain management was assessed using a study-specific 5-point Likert scale. Higher scores indicated greater satisfaction with pain management.
Time frame: Postoperative days 7 and 14
Number of Participants With Treatment-Related Adverse Events
Treatment-related adverse events were assessed using study-specific questions. Recorded events included daytime somnolence, falls, confusion, and other patient-reported complications.
Time frame: Through postoperative day 14
Average Sleep Duration
Average postoperative sleep duration was assessed by patient self-report using a study-specific question and recorded as the average number of hours slept.
Time frame: Postoperative days 7 and 14
Nocturnal Awakenings
Nocturnal awakenings during the postoperative period were assessed using a study-specific question
Time frame: Postoperative days 7 and 14
Plan to share: Yes — Deidentified individual participant data (IPD) that underlie the results reported in the published article will be made available. The shared dataset may include baseline demographic and clinical characteristics, treatment allocation, postoperative sleep and pain assessments, analgesic use, rehabilitation and mobility outcomes, patient satisfaction, and reported adverse events. All data will be deidentified prior to sharing to protect participant confidentiality. No personally identifiable information will be shared.
Supporting information: Study protocol
Time frame: Data will be available beginning 6 months after publication of the study results and will remain available for 5 years.
Access criteria: Deidentified individual participant data and supporting information will be made available to qualified researchers upon reasonable request to the corresponding author. Requests should include a brief research proposal describing the purpose of the analysis and the data requested. Access will be granted following review and approval by the study investigators, provided that the proposed use is scientifically appropriate and consistent with participant confidentiality and applicable ethical requirements.
Ran from Aug 2025 to primary completion in Jun 2026, 10 months.
Of 52 non-industry phase 4 interventional studies under Sleep Initiation and Maintenance Disorders, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 59. This study's 10 months is below that.
Counting every sponsor, half of 57 studies reached it within 28 months; a quarter within 17 and three quarters within 55.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Zolpidem
Sleep Initiation and Maintenance Disorders →